Pfizer targets monthly dosing for GLP-1 therapy (PFE:NYSE)
· seekingalpha.com
Pfizer (PFE) stock is in focus as mid-stage trial data support a once-monthly dosing regimen for GLP-1 therapy berobenatide. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...